Gilead + Merck, innovative long-acting HIV therapy will start phase II clinical trials!

Today, Gilead and Merck & Co.
announced that they will start a phase II clinical study to evaluate the effectiveness of the weekly islatravir/lenacapavir oral combination therapy for HIV-infected patients who are virologically suppressed after antiretroviral therapy.

.

In this phase II clinical research trial, 75 participants who meet all eligibility criteria will be randomly assigned at a 2:1 ratio, and participants will receive a 48-week study drug
.

The primary endpoint is the proportion of study participants with HIV-1 RNA viral load ≥ 50 c/mL at week 24
.

Lenacapavir is a potential first-in-class, research-based, long-acting HIV-1 capsid inhibitor of Gilead.
Lenacapavir's multi-stage mechanism of action is different from the currently approved antiviral drugs.
It is aimed at people who are HIV-1 infected or at risk of infection.
Provide new ways to develop long-term treatment programs
.

Although most antiviral drugs only act on one stage of virus replication, Lenacapavir inhibits multiple stages of the HIV-1 life cycle
.

islatravir (MK-8591) is Merck’s research nucleoside reverse transcriptase translocation inhibitor and is being evaluated in more than 10 clinical trials, including the combined use of islatravir with other antiretroviral drugs
.

It is reported that both islatravir and lenacapavir have a long half-life and have shown low-dose activity in independent clinical studies, which supports their development as an investigative combination of oral and injectable long-acting preparations
.

Although a daily single-tablet oral regimen is available for people living with HIV, the option of an oral or injection regimen that allows less frequent dosing has the potential to address preference considerations and issues related to stigma, compliance, and privacy
.

At present, Lenacapavir and islatravir are used alone or in combination.
They are in clinical studies and have not been approved anywhere in the world.
Their safety and effectiveness have not yet been determined.
However, the combination therapy of the two companies this time may help solve various problems.
The different needs and preferences of AIDS patients
.

End reference materials: [1]https:// -and-investigational-islatravir-for-hiv-1-treatment-in-virologically-suppressed-adul/Past selected onlookers for the first time! Pig kidneys have been successfully used for human transplantation.
These companies have already "run away" the hot literature life is "saving" from the mouth? Nature sub-Journal: In fact, "when to eat" is more important than "eat less" in the history of hot literature The strong "food compass" is here! See how unhealthy the things you usually like to eat.
.
.
Rewen stayed up all night and had a heart break! Nature Sub-Journal: Staying up late disrupts the circadian rhythm of the heart, increases the risk of sudden death, and adds scientific evidence that there is no need for a kidney transplant! Nature Sub-Journal: Scientists Reveal the Plasticity of the Kidney by Reversing Polycystic Kidney Disease in Mice Medical Immunotherapy Research/Translational Medicine Leukemia| Lung Cancer| Stomach Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Diseases| Neurodegenerative Diseases| Intestinal Microbiological Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Printing | Genetic testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy Anti-cancer drugs | 4+7 volume procurement | Consumables | Record system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical Equipment | Telemedicine | Same-share market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D investment |